British Journal of Cancer Q1 Unclaimed

Nature Publishing Group United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

British Journal of Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 236. It is an CC BY Journal with a Single blind Peer Review review system, and It has a price of 2700 €. The scope of the journal is focused on Clinical Cancer, Oncology, Radiotherapy, Chemotherapy. It has an SJR impact factor of 2,833 and it has a best quartile of Q1. It is published in English.

British Journal of Cancer focuses its scope in these topics and keywords: cancer, breast, cell, study, lung, patients, expression, tumour, chemotherapy, human, ...

Type: Journal

Type of Copyright: CC BY

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -


2700 €

Gold OA


Green OA

- €

Non OA


British Journal of Cancer


SJR Impact factor


H Index


Total Docs (Last Year)


Total Docs (3 years)


Total Refs


Total Cites (3 years)


Citable Docs (3 years)


Cites/Doc (2 years)



Aims and Scope

cancer, breast, cell, study, lung, patients, expression, tumour, chemotherapy, human, control, effects, risk, ovarian, colorectal, carcinoma, advanced, protein, case, tissue, growth, effect, Clinical Cancer, Oncology, Radiotherapy, Chemotherapy

Best articles

"Concomitant immunity" in murine tumours of non-detectable immunogenicity

View more

A Bayesian adaptive design for biomarker trials with linked treatments

View more

A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro

View more

A recombinant single chain antibody interleukin-2 fusion protein

View more

A visual summary of the EUROCARE-4 results: a UK perspective

View more

Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy

View more

Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer

View more

Antibodies against lytic and latent Kaposi's sarcoma-associated herpes virus antigens and lymphoma in the European EpiLymph case-control study

View more

Approaches to improving breast screening uptake: evidence and experience from Tower Hamlets

View more

Aspirin use and lung cancer in men

View more

Bladder cancer in cancer patients: population-based estimates from a large Swedish study

View more

Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors

View more

Cancer risk and occupational exposure to aflatoxins in Denmark

View more

Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband

View more

Cancers associated with Kaposi's sarcoma (KS) in AIDS: a link between KS herpesvirus and immunoblastic lymphoma

View more

Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma

View more

Chemotherapy for ovarian cancer: yesterday, today and tomorrow

View more

ChlVPP combination chemotherapy for Hodgkin's disease: long term results

View more

Clinical significance of immune cell infiltration within gallbladder cancer

View more

Cognitive behaviour therapy for fatigued cancer survivors: long-term follow-up

View more

Comparison of standard and double reading and computer-aided detection (CAD) of interval cancers at prior negative screening mammograms: blind review

View more


View more

Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma

View more

Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells

View more


No comments ... Be the first to comment!